- Home
- FOA vs NGNE Comparison
FOA vs NGNE Comparison
Compare FOA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- NGNE
- Stock Information
- Founded
- FOA 2013
- NGNE 2003
- Country
- FOA United States
- NGNE United States
- Employees
- FOA N/A
- NGNE N/A
- Industry
- FOA Finance Companies
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- NGNE Health Care
- Exchange
- FOA Nasdaq
- NGNE Nasdaq
- Market Cap
- FOA 272.8M
- NGNE 325.3M
- IPO Year
- FOA N/A
- NGNE N/A
- Fundamental
- Price
- FOA $21.96
- NGNE $23.87
- Analyst Decision
- FOA Buy
- NGNE Strong Buy
- Analyst Count
- FOA 2
- NGNE 7
- Target Price
- FOA $27.50
- NGNE $41.86
- AVG Volume (30 Days)
- FOA 149.6K
- NGNE 218.5K
- Earning Date
- FOA 11-05-2025
- NGNE 11-14-2025
- Dividend Yield
- FOA N/A
- NGNE N/A
- EPS Growth
- FOA N/A
- NGNE N/A
- EPS
- FOA 7.10
- NGNE N/A
- Revenue
- FOA $527,520,999.00
- NGNE N/A
- Revenue This Year
- FOA $21.21
- NGNE N/A
- Revenue Next Year
- FOA $10.95
- NGNE N/A
- P/E Ratio
- FOA $3.10
- NGNE N/A
- Revenue Growth
- FOA 46.94
- NGNE N/A
- 52 Week Low
- FOA $10.00
- NGNE $6.88
- 52 Week High
- FOA $32.40
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- FOA 33.97
- NGNE 71.04
- Support Level
- FOA $21.25
- NGNE $17.18
- Resistance Level
- FOA $22.83
- NGNE $24.50
- Average True Range (ATR)
- FOA 1.04
- NGNE 1.60
- MACD
- FOA -0.19
- NGNE 0.76
- Stochastic Oscillator
- FOA 13.27
- NGNE 84.73
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.